Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer:: International Society for Gastrointestinal Hereditary Tumours Collaborative Study

被引:32
作者
Park, Jae-Gahb
Kim, Duck-Woo
Hong, Chang Won
Nam, Byung-Ho
Shin, Young-Kyoung
Hong, Sung-Hye
Kim, Il-Jin
Lim, Seok-Byung
Aronson, Melyssa
Bisgaard, Marie Luise
Brown, Gregor J.
Burn, John
Chow, Elizabeth
Conrad, Peggy
Douglas, Fiona
Dunlop, Malcolm
Ford, James
Greenblatt, Marc S.
Heikki, Jarvinen
Heinimann, Karl
Lynch, Elly L.
Macrae, Finlay
McKinnon, Wendy C.
Moeeslein, Gabriela
Rossi, Benedito Mauro
Rozen, Paul
Schofield, Lyn
Vaccaro, Carlos
Vasen, Hans
Velthuizen, Mary
Viel, Alessandra
Wijnen, Juul
机构
[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Lab Cell Biol,Korean Hereditary Tumor Registry, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110744, South Korea
[3] Natl Canc Ctr, Res Inst & Hosp, Ctr Colorectal Canc, Goyang, South Korea
[4] Natl Canc Ctr, Res Inst & Hosp, Canc Biostat Branch, Goyang, South Korea
[5] Mt Sinai Hosp, Familial Gastrointestinal Canc Registry, Toronto, ON, Canada
[6] Univ Copenhagen, Med Genet Clin, Copenhagen, Denmark
[7] Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia
[8] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England
[9] Ctr Life, No Reg Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England
[10] Univ Calif San Francisco, Colorectal Canc Prevent Program, San Francisco, CA 94143 USA
[11] Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland
[12] Stanford Univ, Sch Med, Div Oncol, Canc Genet Clin, Stanford, CA 94305 USA
[13] Univ Vermont, Coll Med, Familial Canc Program, Burlington, VT USA
[14] Univ Helsinki, Cent Hosp, Dept Surg, Helsinki, Finland
[15] Univ Basel, Div Med Genet, Res Grp Human Genet, Basel, Switzerland
[16] St Josefs Hosp Bochum Linden, Dept Surg, Bochum, Germany
[17] Hosp Canc AC Camargo, Pelv Surg Dept, Sao Paulo, Brazil
[18] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol, Tel Aviv, Israel
[19] Genet Serv Western Australia, Western Australian Familial Canc Registry, Subiaco, WA, Australia
[20] Hosp Italiano Buenos Aires, Program Hereditary Canc, Buenos Aires, DF, Argentina
[21] Netherlands Fdn Detect Hereditary Tumours, Leiden, Netherlands
[22] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands
[23] Ctr Riferimento Oncol, I-33081 Aviano, Italy
基金
英国医学研究理事会;
关键词
D O I
10.1158/1078-0432.CCR-05-2452
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of study was to determine the clinical characteristics and mutational profiles of the mismatch repair genes in hereditary nonpolyposis colorectal cancer (HNPCC) patients with small bowel cancer (SBC). Experimental Design: A questionnaire was mailed to 55 members of the International Society for Gastrointestinal Hereditary Tumours, requesting information regarding patients with HNPCC-associated SBC and germ line mismatch repair gene mutations. Results: The study population consisted of 85 HNPCC patients with identified mismatch repair gene mutations and SBCs. SBC was the first HNPCC-associated malignancy in 14 of 41 (34.1%) patients for whom a personal history of HNPCC-associated cancers was available. The study population harbored 69 different germ line mismatch repair gene mutations, including 31 mutations in MLH1, 34 in MSH2, 3 in MSH6, and 1 in PMS2. We compared the distribution of the mismatch repair mutations in our study population with that in a control group, including all pathogenic mismatch repair mutations of the International Society for Gastrointestinal Hereditary Tumours database (excluding those in our study population). In patients with MSH2 mutations, patients with HNPCC-associated SBCs had fewer mutations in the MutL homologue interaction domain (2.9% versus 19.9%, P = 0.019) but an increased frequency of mutations in codons 626 to 733, a domain that has not previously been associated with a known function, versus the control group (26.5% versus 2.8%, P < 0.001). Conclusions: In HNPCC patients, SBC can be the first and only cancer and may develop as soon as the early teens. The distribution of MSH2 mutations found in patients with HNPCC-associated SBCs significantly differed from that found in the control group (P < 0.001).
引用
收藏
页码:3389 / 3393
页数:5
相关论文
共 25 条
  • [21] SANDRINE J, 2002, BIOCHIMIE, V87, P27
  • [22] HNPCC-associated small bowel cancer:: Clinical and molecular characteristics
    Schulmann, K
    Brasch, FE
    Kunstmann, E
    Engel, C
    Pagenstecher, C
    Vogelsang, H
    Krüger, S
    Vogel, T
    Knaebel, HP
    Rüschoff, J
    Hahn, SA
    Knebel-Doeberitz, MV
    Moeslein, G
    Meltzer, SJ
    Schackert, HK
    Tympner, C
    Mangold, E
    Schmiegel, W
    Epplen, JT
    Müller, KM
    Pox, C
    Stemmler, S
    Willert, J
    Büttner, R
    Friedl, W
    Girmscheid, J
    Himer, A
    Lamberti, C
    Mathiak, M
    Propping, P
    Sauerbruch, T
    Siberg, K
    Goecke, T
    Hansmann, A
    Höwer, S
    Poremba, C
    Unger, A
    Wieland, C
    Aust, D
    Balck, F
    Bier, A
    Höhl, R
    Kreuz, FR
    Pistorius, S
    Plaschke, J
    Cremer, F
    Gebert, J
    Keller, M
    Kienle, P
    Kloor, M
    [J]. GASTROENTEROLOGY, 2005, 128 (03) : 590 - 599
  • [23] MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers:: A study of hereditary nonpolyposis colorectal cancer families
    Vasen, HFA
    Stormorken, A
    Menko, FH
    Nagengast, FM
    Kleibeuker, JH
    Griffioen, G
    Taal, BG
    Moller, P
    Wijnen, JT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (20) : 4074 - 4080
  • [24] WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO
  • [25] 2-#